Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer

Keros Therapeutics, Inc. (NASDAQ: KROS) has announced the final results of its cash tender offer to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of US$17.75 per share, for an aggregate purchase price of up to US$194.4 million. The Tender Offer expired on November 18, 2025, concluding the Company’s previously announced US$375 million capital return program. On November 20, 2025, the Company announced that it has accepted for purchase a total of 10,950,165 shares of its common stock, for an aggregate purchase price of US$194.4 million.

Latham & Watkins LLP represented the dealer manager in the Tender Offer with a Capital Markets team led by partners Greg Rodgers and Nathan Ajiashvili, with associate Brice Stewart, and with assistance from Alondra Tlatelpa. Advice was also provided on tax matters by partner Eric Cho, with assistance from Daniel Mousseri.